Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guy Griebel

Showing results (51-60 of 68) with videos related to

Pageof 7
Sort By:
Scientific Reports|February 7, 2018
The selective reversible FAAH inhibitor, SSR411298, restores the development of maladaptive behaviors to acute and chronic stress in rodentsGuy Griebel, Jeanne Stemmelin, Mati Lopez-Grancha, et al.
Pharmacology, Biochemistry, and Behavior|December 1, 2010
The neurokinin NK2 antagonist, saredutant, ameliorates stress-induced conditions without impairing cognitionNancy Rogacki, Matilde Lopez-Grancha, Vanessa Naimoli, et al.
Bioorganic & Medicinal Chemistry Letters|October 1, 2013
Discovery of a potent, selective, and orally bioavailable histamine H3 receptor antagonist SAR110068 for the treatment of sleep-wake disordersZhongli Gao, William J Hurst, Werngard Czechtizky, et al.
Scientific Reports|December 4, 2019
The selective GSK3 inhibitor, SAR502250, displays neuroprotective activity and attenuates behavioral impairments in models of neuropsychiatric symptoms of Alzheimer's disease in rodentsGuy Griebel, Jeanne Stemmelin, Mati Lopez-Grancha, et al.
CNS Drug Reviews|February 22, 2003
SL651498, a GABAA receptor agonist with subtype-selective efficacy, as a potential treatment for generalized anxiety disorder and muscle spasmsGuy Griebel, Ghislaine Perrault, Jacques Simiand, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 20, 2002
SSR240600 [(R)-2-(1-[2-[4-[2-[3,5-bis(trifluoromethyl)phenyl]acetyl]-2-(3,4-dichlorophenyl)-2-morpholinyl]ethyl]-4-piperidinyl)-2-methylpropanamide], a centrally active nonpeptide antagonist of the tachykinin neurokinin 1 receptor: II. Neurochemical and behavioral characterizationRégis Steinberg, Richard Alonso, Liliane Rouquier, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|August 29, 2006
SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophreniaPhilippe Pichat, Olivier E Bergis, Jean-Paul Terranova, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|June 16, 2005
Disruption of the prepulse inhibition of the startle reflex in vasopressin V1b receptor knockout mice: reversal by antipsychotic drugsNobuaki Egashira, Akito Tanoue, Fuminori Higashihara, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 28, 2002
Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonistClaudine Serradeil-Le Gal, Jean Wagnon, Jacques Simiand, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|April 27, 2007
Stimulation of the beta3-Adrenoceptor as a novel treatment strategy for anxiety and depressive disordersJeanne Stemmelin, Caroline Cohen, Jean-Paul Terranova, et al.
Pageof 7

Showing results (51-60 of 68) with videos related to

Sort By:
Pageof 7
Scientific Reports|February 7, 2018
The selective reversible FAAH inhibitor, SSR411298, restores the development of maladaptive behaviors to acute and chronic stress in rodentsGuy Griebel, Jeanne Stemmelin, Mati Lopez-Grancha, et al.
Pharmacology, Biochemistry, and Behavior|December 1, 2010
The neurokinin NK2 antagonist, saredutant, ameliorates stress-induced conditions without impairing cognitionNancy Rogacki, Matilde Lopez-Grancha, Vanessa Naimoli, et al.
Bioorganic & Medicinal Chemistry Letters|October 1, 2013
Discovery of a potent, selective, and orally bioavailable histamine H3 receptor antagonist SAR110068 for the treatment of sleep-wake disordersZhongli Gao, William J Hurst, Werngard Czechtizky, et al.
Scientific Reports|December 4, 2019
The selective GSK3 inhibitor, SAR502250, displays neuroprotective activity and attenuates behavioral impairments in models of neuropsychiatric symptoms of Alzheimer's disease in rodentsGuy Griebel, Jeanne Stemmelin, Mati Lopez-Grancha, et al.
CNS Drug Reviews|February 22, 2003
SL651498, a GABAA receptor agonist with subtype-selective efficacy, as a potential treatment for generalized anxiety disorder and muscle spasmsGuy Griebel, Ghislaine Perrault, Jacques Simiand, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 20, 2002
SSR240600 [(R)-2-(1-[2-[4-[2-[3,5-bis(trifluoromethyl)phenyl]acetyl]-2-(3,4-dichlorophenyl)-2-morpholinyl]ethyl]-4-piperidinyl)-2-methylpropanamide], a centrally active nonpeptide antagonist of the tachykinin neurokinin 1 receptor: II. Neurochemical and behavioral characterizationRégis Steinberg, Richard Alonso, Liliane Rouquier, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|August 29, 2006
SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophreniaPhilippe Pichat, Olivier E Bergis, Jean-Paul Terranova, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|June 16, 2005
Disruption of the prepulse inhibition of the startle reflex in vasopressin V1b receptor knockout mice: reversal by antipsychotic drugsNobuaki Egashira, Akito Tanoue, Fuminori Higashihara, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 28, 2002
Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonistClaudine Serradeil-Le Gal, Jean Wagnon, Jacques Simiand, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|April 27, 2007
Stimulation of the beta3-Adrenoceptor as a novel treatment strategy for anxiety and depressive disordersJeanne Stemmelin, Caroline Cohen, Jean-Paul Terranova, et al.
Pageof 7